Sunshine Biopharma Inc. (NASDAQ: SBFM) launched generic Ondansetron tablets in Canada on September 24, 2026, expanding its oncology supportive care portfolio. The launch introduces 4 mg and 8 mg film-coated tablets for nausea and vomiting associated with chemotherapy, radiation therapy, and surgery.

The product is the generic equivalent of the brand name Zofran. It functions as a prescription serotonin 5-HT3 receptor antagonist by blocking chemicals that trigger nausea and vomiting. Offering two strengths allows healthcare providers to tailor treatment to individual patient needs and physical conditions.

Market opportunity and growth drivers

The global Ondansetron market was valued at $1.82 billion in 2025 and is projected to reach $2.98 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.6%, according to DataIntelo. Growth is driven by escalating cancer diagnoses worldwide, an increased number of surgical procedures, and broad adoption across multiple clinical indications.

The Canadian pharmaceutical market accounts for approximately 2.1% of the global market and ranks as the sixth largest worldwide, per IQVIA Pharmafocus 2028. Sunshine Biopharma leverages its wholly owned Canadian subsidiary, Nora Pharma Inc., which maintains a robust distribution network across the country.

Portfolio expansion and pipeline

Sunshine Biopharma currently markets 61 generic prescription drugs in Canada, with approximately 11 additional drugs scheduled for launch in the remainder of 2026. The addition of Ondansetron represents a strategic expansion into the area of nausea and vomiting caused by cancer therapy.

Dr. Steve Slilaty, CEO, stated that launching Ondansetron oral tablets represents another decisive step in scaling the company's generics business. He noted the product enhances competitive position and reflects a commitment to broadening access to dependable pharmaceuticals.

What the numbers show

The company's immediate commercial focus is supported by its established distribution infrastructure through Nora Pharma. With 61 generics already on the market and 11 more planned for 2026, the addition of Ondansetron increases the total number of marketed products to at least 73 within the fiscal year, assuming successful launches of the scheduled items. This expansion occurs alongside proprietary drug development programs for K1.1 mRNA (liver cancer) and PLpro protease inhibitor (SARS Coronavirus infections).

Sunshine Biopharma CEO Steve Slilaty approved a reverse stock split of up to 1-for-20 by written consent. Slilaty holds about 97% of the company's voting power.

The corporate action was executed without a formal shareholder meeting, relying instead on written consent from the controlling shareholder. This mechanism allows for rapid implementation of capital structure changes when majority approval is secured.

Governance and Control

Slilaty's dominant stake ensures that his consent effectively determines the outcome of this specific corporate action. The high concentration of voting power simplifies decision-making processes for structural adjustments like stock splits.

The company filed relevant documents with the SEC, including Form 8-K and Schedule 13D amendments, detailing the transaction and ownership structure.